Sanofi will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, CT, for $650 million upfront and as much as $100 million based on certain development milestones. The acquisition, subject to customary regulatory approvals, is expected to close in 3Q17.
 
Protein Sciences received approval from the FDA in October 2016 for their Flublok Quadrivalent Influenza Vaccine (QIV), which is the only recombinant protein-based flu vaccine approved by the FDA. 
 
“The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine,” said David Loew, Sanofi executive vice president and head of Sanofi Pasteur, Sanofi’s vaccines division. 

“Protein Sciences was actively looking for an opportunity to grow its business, particularly in the U.S.,” said Manon M.J. Cox, president and chief executive officer, Protein Sciences. “As part of Sanofi Pasteur, we expect our Flublok influenza vaccine to benefit from Sanofi Pasteur’s expertise in the field of influenza vaccines.”